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ABSTRACT: Nine hundred million people are infected with the soil-
transmitted helminths Ascaris lumbricoides (roundworm), hookworm, and
Trichuris trichiura (whipworm). However, low single-dose cure rates of the
benzimidazole drugs, the mainstay of preventative chemotherapy for whipworm,
together with parasite drug resistance, mean that current approaches may not be
able to eliminate morbidity from trichuriasis. We are seeking to develop new
anthelmintic drugs specifically with activity against whipworm as a priority and
previously identified a hit series of dihydrobenzoxazepinone (DHB) compounds
that block motility of ex vivo Trichuris muris. Here, we report a systematic
investigation of the structure−activity relationship of the anthelmintic activity of
DHB compounds. We synthesized 47 analogues, which allowed us to define features of the molecules essential for anthelmintic
action as well as broadening the chemotype by identification of dihydrobenzoquinolinones (DBQs) with anthelmintic activity. We
investigated the activity of these compounds against other parasitic nematodes, identifying DHB compounds with activity against
Brugia malayi and Heligmosomoides polygyrus. We also demonstrated activity of DHB compounds against the trematode Schistosoma
mansoni, a parasite that causes schistosomiasis. These results demonstrate the potential of DHB and DBQ compounds for further
development as broad-spectrum anthelmintics.
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Nine hundred million people are infected with soil-transmitted
helminths, causing a global burden of around two million
disability-adjusted life years.1,2 Because of this, the World
Health Organization has set a goal to achieve and maintain
elimination of soil-transmitted helminth morbidity by 2030.3
Huge mass drug administration efforts are underway,
distributing hundreds of millions of doses of benzimidazole
drugs (albendazole and mebendazole, Figure 1) to school-age
children in affected areas annually or biannually as preventative
chemotherapy (PCT).
Benzimidazole drugs are partially effective against whipworm
(Trichuris trichiura) when administered as a course of
treatment, reaching cure rates of around 43%.4 However, for
mass drug administration, practicalities and scale mean that
only one dose is given. In contrast to Ascaris lumbricoides,
where a single dose of benzimidazole drugs cures around 90−
95% of infected individuals, the single dose cure rate for
whipworm is low, around 30%.5,6 The current mass drug
administration protocol may therefore not be able to break
transmission and reduce the prevalence of moderate to heavy
whipworm infections to below 2% as required to eliminate
morbidity.3 Due to the poor single dose efficacy of the
benzimidazole drugs against whipworm, there have been
extensive efforts to identify more efficacious drug combina-
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Figure 1. Structures of albendazole and mebendazole.
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tions.6 Of these, the most promising to date is a combination
of albendazole plus the N-type nicotinic acetylcholine receptor
agonist oxantel pamoate, which has a single dose cure rate
reported to be between 31 and 83%.7−10 Albendazole plus
ivermectin is the only approved drug combination for
whipworm with a single dose cure rate of approximately
60%.6 A second drug, moxidectin, also shows promise to be
added to albendazole for improved control of whipworm.7
Of concern, however, is the possibility that drug resistance
may become prevalent, derailing the push toward control of
whipworm. Currently, there is only indirect evidence of this
possibility. In a meta-analysis, it has been shown that egg
reduction rates and cure rates after albendazole treatment have
been decreasing over time.11 Polymorphisms in the beta-
tubulin gene that are associated with benzimidazole resistance
are found in populations of human whipworm, and the
frequency of these polymorphisms increased after albendazole
treatment.12,13
The problem of resistance to anthelmintics is emphasized by
the experience from veterinary medicine. Indeed, all currently
approved anthelmintics were discovered primarily for the
animal health market, with the key drugs levamisole,
mebendazole, albendazole, and ivermectin approved between
1968 and 1981.14 Unfortunately, resistance in target species
was reported rapidly after they entered use, most notably in the
important sheep and goat parasite Haemonchus contortus.15
More recently, new drug classes such as the amino-acetonitrile
derivative monepantel have been introduced, but resistance
again emerged swiftly, within six years of farm use.16 Although
there are some differences, such as treatment frequency, the
same selective pressure that drives anthelmintic resistance on
farms acts on the populations of human parasitic helminths
that are exposed to incompletely effective doses of
anthelmintics on a huge scale in mass drug administration
(MDA) programs.17
Because of these two problemslow efficacy of existing
drugs against whipworm and concerns about development of
resistance to these drugswe and others have been pursuing a
strategy of identifying new antiwhipworm compounds via a
mixture of repurposing and de novo small molecule screen-
ing.18−25 Underscoring the need for this work, the recent
WHO roadmap for neglected tropical diseases 2021−2030
assesses that developing more effective medicines and drug
combinations against T. trichiura and hookworm is a critical
action required to meet the target for elimination of soil-
transmitted helminths as a public health problem by 2030.26
Beyond soil transmitted helminths (STH), lymphatic
filariasis and schistosomiasis are two medically important
tissue helminthiases prioritized for global or regional
elimination as a public health problem via preventative
chemotherapy (PCT), as outlined in the WHO Roadmap
2030 implementation targets.26 A related filarial nematode,
Onchocerca volvulus, is also targeted for regional elimination
and interruption of transmission.
Lymphatic filariasis is caused by infection with the nematode
parasites Brugia malayi, B. timori, and Wuchereria bancrof ti.
Current PCT uses a combination of albendazole, diethylcarba-
mazine citrate (DEC), and ivermectin, which has been shown
to have a partial macrofilaricidal effect against W. bancrof ti.27,28
Unfortunately, in countries where onchocerciasis is endemic,
DEC is contraindicated, and where Loa loa is found,
ivermectin is contraindicated. This prevents use of the triple
therapy as PCT in some regions, and ideally, a new drug that
can achieve macrofilaricidal (i.e., curative) efficacy but is safe
to administrate in the context of loiasis and onchocerciasis will
be developed. One promising therapeutic strategy is antibiotics
that target the Wolbachia endosymbiont.29
Onchocerciasis is caused by another filarial nematode, O.
volvulus. The current recommendation for PCT is once or
twice yearly ivermectin sustained for ten or more years.26
Recently, moxidectin has been shown to be superior to
ivermectin as microfilaricide.30 However, moxidectin, like
ivermectin, is a macrocyclic lactone, and as demonstrated in
veterinary medicine and model systems, cross-resistance is
likely.31 There is promise for the future, with emodepside,
oxfendazole, and the anti-Wolbachia agents ABBV-4083 and
AWZ1066 in early clinical development.32−34
Moving beyond nematodes, schistosomiasis is caused by
infection with Schistosoma trematodes such as S. mansoni.
There are two types of disease: intestinal schistosomiasis and
urogenital schistosomiasis, causing a burden of around 2.5
million disability-adjusted life years (DALYs).26 Praziquantel is
the only drug used for treatment of human schistosomiasis.
The mechanism of praziquantel action remained unclear for a
long time, but recently, it has shown to be an activator of a
transient receptor potential (TRP) channel.35
Reliance of current PCT protocols on a few, or in the case of
onchocerciasis and schistosomiasis, a single chemotherapeutic
agent (ivermectin, potentially replaced by moxidectin, and
praziquantel, respectively) is a vulnerability of current
elimination strategies, considering the potential for develop-
ment of drug resistance. As with STH, annual or semiannual
mass drug administrations extending upward of 20 years are
required to break transmission with current drugs due to
incomplete adulticidal/selective larvicidal activity profiles of
the implemented antifilarial or schistosomicidal agents.
Alternative strategies, for instance, development of a short-
course curative treatment for filariasis, would be a step-change
to reduce elimination time frames.36,37 Schistosome resistance
to praziquantel can be induced after sublethal drug treatment
of parasites in the laboratory, and reduced susceptibility of S.
mansoni to the drug has been reported in the field.38 Again, the
WHO has assessed that developing new, alternative medicines
to complement praziquantel in case of resistance is a critical
action to achieve the 2030 roadmap goal of schistosomiasis
control.26
We previously described a hit series of five dihydrobenz[e]-
[1,4]oxazepin-2(3H)-one (DHB) compounds with anthelmin-
tic activity against ex vivo T. muris.21 Here, we report our
progress in expanding this hit series and understanding the
relationship between structure and anthelmintic activity. We
also extend our investigations of the activity of the DHB
compounds against Brugia malayi, a causative agent of
lymphatic filariasis, Heligmosomoides polygyrus bakeri, a mouse
gastrointestinal nematode model, and the human blood fluke,
Schistosoma mansoni.
■ RESULTS
Novel DHB Chemistry. We recently reported the
identification of five DHB hit compounds as a new family of
molecules active against T. muris adult motility.21 Further, one
of the compounds 1 (OX02983) was also found to be
efficacious at reducing the ability of eggs to establish infection
in vivo. As we identified a limited number of active DHB family
members in the first instance via a library screen, we aimed to
investigate the DHB chemotype systematically with the goal of
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understanding their structure−activity relationships (SARs)
and improving potency. Compound 1 (OX02983) was used as
a starting point of our investigation.
The synthesis used to prepare DHB 1 was adapted to
systematically alter all of the different cycles A−D, as shown in
Figure 2. The first step was a reductive amination of the
requisite aminobromobenzoate with the desired aldehyde to
install cycles A and C. This was followed by a ring-closure step
to generate cycle B and finally a cross-coupling reaction to add
cycle D (Scheme 1).
It was decided to conduct a systematic SAR investigation
and alter the four different cycles within the structure of 1 to
understand their importance in the activity against T. muris
with a view to improving efficacy. As the synthesis is linear, it
was logical to investigate from A to D. We therefore started
with core B to ascertain the importance of regiochemistry and
relative orientation of the substituents (Table 1). All of the
prepared compounds were screened using an automated adult
T. muris motility assay39 at 100 μM. Active compounds were
also tested at lower concentrations and/or an EC50 value
determined to assess their relative activity.
Using the appropriate starting materials (see the Supporting
Information File 1 for details of the syntheses), the different
structural analogues 5, 6 (where the 4-pyridyl ring is in
position 8 and 6 of the bicyclic core respectively, see Figure 2),
and 7 (the reverse amide equivalent of 1) were prepared using
a synthesis similar to that of 1 (Table 1). Interestingly, none of
the structural analogues exhibited any activity in our ex vivo
adult T. muris motility assay, revealing that the regiochemistry
within 1 is important for its activity. The next step was to
investigate cycle C; a small set of amines was used in the
reductive amination step to prepare analogues 10, 11, 12, 8,
and 9 bearing methyl, cyclopropyl, cyclohexyl, benzyl, and p-
trifluoromethylbenzyl groups, respectively. From those, only
the cyclohexyl substituted derivative 12 and the p-trifluor-
omethylbenzyl substituted derivative 9 showed activity in the
motility assay with EC50 values of 52 and 26 μM respectively.
The next step was to vary cycle D while keeping cycles A−C
constant to allow a comparison with 1. Suzuki reactions were
therefore carried out on the 7-bromo precursor with an array
of boronic acids and esters. The regioisomers of the pyridyl
ring (D) were tolerated with meta and para giving the best
activity. Analogues where the pyridyl ring was replaced with an
aryl substituent were all inactive, be they unsubstituted (15),
substituted with an electron withdrawing group (4-F, 16), or
an electron donating group (4-Me, 17) (Table 1). Different
heterocycles were also trialled in place of the pyridine; a similar
level of activity was obtained with the isosteric thiazole (19,
EC50 of 45 μM) and the methylimidazole (20, EC50 of 68 μM)
analogues. Substituting with a pyrimidine (18) led to a loss of
activity, leading us to hypothesize that the basicity of the
substituent may be of importance to the activity. Following
this, we prepared phenylamine and benzyl amine-substituted
analogues 22 and 21, but neither exhibited activity against T.
muris, suggesting that incorporating a linker between cycles A
and D was not tolerated. We then turned our interest to
substituted pyridyl, and although the methoxy substituted
pyridyl (23) was not active, the amino pyridyl 24 displayed
modestly improved activity compared to 1 (EC50 26 μM),
which may be related to its moderately higher basicity.
In an effort to improve the efficacy further, we looked at
more drastic modification to core B by contracting the ring by
removing the oxygen atom. Forge (Cresset) was used to
overlay 1 and its six-membered ring analogue 28; a good fit
was obtained (∼79% similarity), suggesting dihydrobenzoqui-
nolinones (DBQ) as possible candidates for further improve-
ment (Figure 3).
DBQs have been investigated quite extensively in medicinal
chemistry; examples have been reported as antiviral agents
through inhibition of HIV replication.40,41 Other analogues
were found to inhibit WDR5 protein−protein interactions,
leading to inhibition of cancer cell proliferation.42−44
It was decided to prepare a small number of compounds
only using those substituents and comparable regiochemistry
that gave the most potent analogues so far.
The synthesis started with substitution at N2 of 6-bromo-
3,4-dihydroisoquinolinone 26 with 4-methylbenzyl bromide,
followed by a Suzuki coupling reaction with the requisite
boronic acid to afford the desired ring contracted 1 mimic, 28
(Scheme 2).
The DBQs bearing the 3-and 4-pyridyl substituents (28 and
29) were active in the motility assay and led to similar EC50
values to the best results from the DHB series (with EC50
values of 21 and 46 μM, respectively). Unfortunately, as soon
as we moved away from the simple pyridyl substituent, all
activity in the motility assay was lost again. The 2-amino pyrid-
Figure 2. Structure of 1 (OX02983) highlighting the four cycles
labeled A−D.
Scheme 1. Representative Scheme for Synthesis of DHB Compoundsa
a(i) 4-Methylbenzaldehyde (1.5 equiv), AcOH (0.5 equiv), NaBH(OAc)3, CH2Cl2, 0 °C to rt, 48 h; (ii) LiAlH4 (1 M in THF, 3.5 equiv); (iii)
chloroacetyl chloride (2.0 equiv), NEt3 (2.0 equiv), THF, 0 °C to rt, 16 h; (iv) NaOH (10 N, aq.), rt, 2 h; (v) 4-pyridyl-B(OH)2 (1.1 equiv),
Pd(dppf)Cl2 (5 mol %), K2CO3 (3.0 equiv), 1,4-dioxane/H2O (4:1), 90 °C, 18 h.
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Table 1. Structures and EC50 Values of Representative DHB Compounds in the T. muris Adult Motility Assay
a
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Table 1. continued
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5-yl, the best example of ring D in the DHB series, was
surprisingly inactive (30 EC50 > 100 μM vs 24 EC50 26 μM).
Similarly, the methyl imidazole and the thiazole-substituted
analogues (31 and 32, respectively) also exhibited no activity
in the motility assay, in contrast to their DHB counterparts,
suggesting that SARs did not correlate between the DHB and
DBQ series. As the best results from the DBQ and the DHB
series were largely similar, we felt that this alternative core was
not going to substantially enhance the potency of the
compounds.
Collectively, these data have improved our understanding or
provided insights into the SARs of the DHB/DBQ family of
compounds. The structure of cycles A and B in 1 were found
to be critical to activity; variations of the toluyl group for ring
C generally also led to inactive compounds. Some variations of
cycle D were tolerated, and there appeared to be a preference
for a basic site within the substituent. However, although we
were able to alter the structure resulting in loss of activity, we
were unable to improve, only retain, activity.
Table 1. continued
aAll compounds investigated in this study are described in the Supporting Information File S2. No activity means no clear reduction in motility
when tested at 100 μM. Where an EC50 estimate is shown, it was calculated using a log-logistic model using the R package drc;
45 clogP values were
calculated using ChemDraw Professional (16.0.0.82 (68)).
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Apart from the representative compounds presented in
Table 1, further similar analogues and all synthetic precursors
were prepared and tested (Supporting Information File 2).
Together, the results gave us a library of 47 compounds that
could then be used against different parasite species to
understand whether these compound series showed broad-
spectrum anthelmintic activity.
DHB Compounds Are Active in Models of a Range of
Helminth Infections. Development of a new anthelmintic is
a long and expensive process, and funding for neglected
tropical diseases is limited. Furthermore, multiple parasitic
helminths, for example the soil transmitted nematodes Ascaris,
Trichuris, and the human hookworms, the vector transmitted
filarial nematodes, and the Schistosoma trematodes, are often
endemic in the same regions. It would, therefore, be helpful if a
new drug would have activity against several target species and
worked across the Nematoda and Platyhelminthes phyla. We
therefore wanted to investigate whether the DHB series of
compounds had a range of activities beyond Trichuris.
Activity against B. malayi. We first examined single dose
efficacy of 33 DHB compounds at 10 μM against the B. malayi
mf larval stage with motility scored every 24 h. The results after
6 days are shown in Figure 4A. Ivermectin was used as a
positive control in the mf assay. 1 showed the most promise in
this assay, reducing average motility to a score of 1. From this
primary screen, 15 compounds that were determined to
significantly impact B. malayi mf motility, plus an additional 5
with no discernible effect, were retested in a secondary screen
(Figure 4B). These results confirmed the significant reduction
in motility caused by 11 compounds and confirmed the
paralytic effect of 1. After 6 days of drug exposure, mf were also
tested for metabolic activity, a measure of parasite viability,
using the MTT assay (Figure 4C). The MTT assay is part of
the WHO-approved in vitro assay for antifilarial activity using
O. gutturosa46 and has been previously used for assessment of
B. malayi metabolic status.47−50 1 and 14 in particular showed
activity in this assay, significantly reducing B. malayi mf MTT
reductase activity on average by 53 and 82%, respectively (one-
way ANOVA with Holm−Sidak’s multiple comparison tests, P
< 0.01 and P < 0.0001). The time course of the effect of 1
against mf motility at different concentrations is shown in
Supplementary Figure 3. To determine the dose-dependent
efficacy of 1 and 14, they were tested in a concentration
response 6-day experiment (dose range 0.016−50 μM) using
MTT reductase activity as a quantitative viability readout
(Figure 4D, E). From this, an EC50 concentration of 5.5 μM
was determined for 1 and 26.7 μM for 14.
Due to their efficacy against B. malayi mf, 1 and 14 were
advanced for in vitro activity against adult B. malayi utilizing a
novel, long-term adult worm lymphatic endothelial cell bilayer
coculture system. Adult female B. malayi exposed to vehicle
control retained full survival and motility in culture over 14
days, whereas the positive control, flubendazole (10 μM),
mediated complete paralytic activity by day 14 (Kruskal−
Wallis with Dunn’s multiple comparisons tests, P < 0.001) and
significantly reduced metabolic activity by an average of 72%
(one-way ANOVA with Holm−Sidak’s multiple comparison
tests, P < 0.001) (Figure 4F, G). 1 (10 μM) also mediated
significant antifilarial activities against adult B. malayi by day
14. Motility was completely hindered in 4/6 adult parasites by
1 (Kruskal−Wallis with Dunn’s multiple comparisons tests, P <
0.001), while 14 mediated a 50% partial reduction in adult
motility. 1 also significantly impacted adult female B. malayi
metabolic activity, on average by 41% (one-way ANOVA with
Holm−Sidak’s multiple comparison tests, P < 0.05). Taken
together, these results are encouraging because they show that
compounds that are active against T. muris (a clade I nematode
according to the phylogeny of Blaxter) are also active against
evolutionarily distant nematodes, as B. malayi is a clade III
nematode.51
Activity against H. polygyrus. H. polygyrus bakeri is an
intestinal nematode parasite of laboratory mice.52 It is a
strongylid nematode related to human hookworm species.
Thirty-one DHB compounds were tested at 100 μM against ex
vivo H. polygyrus L3 stage worms (n = 2). The results are
shown in Figure 5. The cutoff used to determine hits in this
assay is 50% larval death.20 Two compounds, 33 and 34,
exceeded this level of larval death and were therefore
considered active. They did not, however, reach the threshold
for good activity (75%). Given the modest activity of these
compounds against H. polygyrus, we have not further pursued
this direction at this point. Activity of DHB compounds against
nematodes in three of the five clades of the phylum Nematoda,
according to the phylogeny of Blaxter, supports the potential
for development of a pan-nematode control agent from this
compound series.51
Activity against S. mansoni Schistosomula. Compared to
T. muris, H. polygyrus, and B. malayi, which are all parasitic
Figure 3. Overlay of 1 (OX02983) (light blue) and 28 (OX3699)
(gray); blue spheres represent negative electrostatic field, red spheres
represent positive electrostatic field, brown spheres represent
hydrophobicity, and small yellow sphere represent the van der
Waals force.
Scheme 2. Synthesis of 28 (OX3699)a
aReagents and conditions: (i) 4-methylbenzyl bromide (2.0 equiv), NaH (1.5 equiv), DMF, rt, 16 h (96%); (ii) 4-pyridyl-B(OH)2 (1.1 equiv),
Pd(dppf)Cl2 (5 mol %), K2CO3 (3.0 equiv), 1,4-dioxane/H2O (4:1), 90 °C 18 h.
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worms within the phylum Nematoda, S. mansoni is a more
evolutionarily distinct helminth, a trematode within the
Platyhelminthes phylum. We screened 30 DHB compounds
against S. mansoni schistosomula at 50 μM using the
Roboworm system. This is an imaging-based screen that
measures two parameters, motility and “phenotype”, an
assessment of morphological and other features.53 Auranofin,
an inhibitor of S. mansoni thioredoxin glutathione reductase
(TGR) activity54 was the positive control in this experiment.
The results are shown in Figure 6. The cut-offs for defining hit
compounds in this assay have been previously defined.53,55
Nine compounds were hits for both motility and phenotype
measurements. Concentration−response curves were meas-
ured for these compounds (Table 2) with EC50 values in the
range 14−41 μM. It is encouraging that DHB compound series
members show activity against such evolutionarily distant
pathogens to whipworm, particularly as DHB compounds
show little or no cytotoxicity in mammalian cell culture, so
these compounds are not broadly toxic.21
■ DISCUSSION
Investigation of the DHB Structure−Activity Rela-
tionship. We previously identified a small hit series of five
DHB compounds with activity against T. muris adult
motility.21 In medicinal chemistry, it is important to under-
stand how variations in the structure of the compound affect
activity, as this allows us to discover the critical aspects of the
compound for target binding with the overall aim of increasing
potency as well as improving physicochemical properties. We
therefore embarked upon a systematic structure−activity
Figure 4. Activity of 33 DHB compounds against B. malayi microfilariae and adults. (A) Primary screen: assessment of B. malayi mf motility (5
point scoring system) after 6 days of continuous exposure to 35 test compounds screened at 10 μM in triplicate. Ivermectin (50 μM) was the
positive control. (B) Confirmatory mf motility and (C) metabolic activity screening of 15 active compounds identified in (A) and 5 inactive
compounds (10 μM in triplicate). (D, E) EC50 assays of active compounds 1 and 14 on B. malayi microfilarial metabolic activity after 6-day
continuous exposure. Metabolic activity (C−E) was assessed by colorimetric MTT assay; data are optical density of mf extracts measured at 490
nm. (F) Effects on adult female B. malayi motility and (G) metabolic activity following 14 days of continuous exposure to 1 or 14 (10 μM).
Flubendazole (10 μM) was used as a positive control in the assay. Data plotted is mean ± SD of 3 replicates (A−E) median and range of 6
replicates (F) and mean ± SEM of 9−11 replicates (G). Significant differences were determined by one-way ANOVA with Holm−Sidak multiple
comparisons test (A−C and G) or Kruskal−Wallis with Dunn’s multiple comparisons test (F). Significance is indicated ****P < 0.0001, ***P <
0.001, **P < 0.01, and *P < 0.05.
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relationship investigation, taking advantage of the convenient
synthesis of the DHBs, which allowed us to systematically alter
the four cyclic components of this class of compounds. A total
of 47 variant compounds were synthesized in this work.
This work has enabled us to define certain essential features
of the antiwhipworm DHB compounds. The 4-pyridyl ring
(cycle D in Figure 2) must be in the 7 position, unlike the
analogues 5 and 6. The amide moiety of the oxazepinone ring
must be as in 1, and not as in 7. The oxazepinone nitrogen can
be substituted with methylbenzyl, cyclohexyl, and p-trifluor-
omethylbenzyl (1, 12, and 9), but not methyl, cyclopropyl, or
benzyl groups. We also investigated in detail the replacement
of cycle B. We found that removal of the oxygen from the
DHB core was also consistent with similar activity to 1: the
dihydrobenzoquinolinone compounds 28 and 29 had EC50
values of 21 and 42 μM, respectively.
DHB Compounds as anti-Trichuris Agents. We
identified the first DHB compounds in a screen of a subset
of the library of Chemistry Research Laboratory, University of
Oxford small molecule library.21 We as yet do not know the
target of the DHB/DBQ compounds, and clearly identifying it
will be immensely helpful to advance the potency of these
compounds. Unfortunately, anthelmintic-resistant mutants or
isolates are, as yet, not available in the T. muris system. No
previous activity that could provide insights into the
mechanism of action has to our knowledge been reported for
the DHB/DBQ compounds described here.
A detailed pharmacokinetic investigation will also be
essential for the future steps of this work. We have reported
calculated cLogP values in Table 1, and these molecules
conform to the “rule of five”. Interestingly, those compounds
retaining anthelmintic activity showed clogP values in the
range of approximately 3−4. However, as McKerrow and
Lipinski have noted, the rule of 5 is less important for
antiparasitic drug development.56 This is because antipar-
asitics, and anthelmintics in particular, have special require-
ments in terms of permeability and other properties to enable
them to reach the target organism and then enter the parasite
and reach the target.57 An ideal therapeutic against the
intestinal nematode parasite Trichuris trichiura (found in the
cecum) would show minimal gastrointestinal absorption (and
rapid hepatic clearance if needed) to maximize exposure in the
cecum. Optimization of these parameters, either via the
properties of the compound itself or by control of formulation,
will be critical to enable the compound to reach the parasite at
high concentration in vivo.58 There is then a further hurdle to
optimize: entry into the nematode itself. Structural features
that enable compounds to cross the nematode cuticle, which is
a barrier to small molecule permeability, are complex.59,60 This
assumes that oral drugs do reach Trichuris by passage to the
cecal lumen then crossing the cuticle, which seems to be the
case for oxantel and mebendazole but is less clear for
albendazole.61 Delivery to parasites in the cecum does present
particular challenges compared to parasites in the stomach or
in the blood, and we hypothesize that lack of optimization of
this may be one reason for the lower efficacy of benzimidazoles
against Trichuris.
Targeting Multiple Helminth Species with DHB
Family Members. Despite being unable to improve efficacy
against T. muris substantially through structural modifications,
we were able to demonstrate activity of our compounds against
other helminth parasites. In drug discovery for NTDs, pan-
anthelmintic activity is desirable given that polyparasitism in
the target population is the norm. Thus, being able to target
multiple species of helminths with a single drug administered
via mass drug administration programs is of significant benefit.
Of particular note was the commonality in DHB compounds
active against T. muris that were also active against the tissue
dwelling nematode parasite, B. malayi. The ability of the DHB
compounds to act against different clades within the nematode
phylum is not unprecedented; indeed, the coadministration of
albendazole with ivermectin is currently advocated for control
of Trichuris, and the same drug combination (in some
situations supplemented with diethylcarbamazine) is widely
used against lymphatic filariasis.28 Indeed, the large-scale
efforts to treat lymphatic filariasis have indirectly enhanced the
number of people being treated for soil transmitted
helminths.62 Similarly, the alternative drug combination of
albendazole and moxidectin is also being explored for the
treatment of trichuriasis given that moxidectin is an approved
treatment for onchocerciasis.63
In contrast, there are currently no drugs used in MDA that
have demonstrated cross-phyla efficacy against both schisto-
Figure 5. Measurement of the activity of 31 DHB compounds against
H. polygyrus L3 stage worms. Larval death is measured as the
proportion of worms that respond to stimulus. Compounds were
tested in duplicate at 100 μM. Dashed lines indicates the cutoff (50%)
used to determine hits in this assay and the cutoff for good activity
(75%):20 <50%, not active; 50−75%, moderate activity; >75%, good;
and >90%, excellent activity.
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somes and nematodes. Currently, only praziquantel is used for
preventative chemotherapy against schistosomes, although
coadministration with albendazole is recommended where
STHs are coendemic.64 Therefore, it was notable that DHB
family members could work across phyla, showing some
activity against both schistosomes and nematodes. We note
that it was unexpected that we found some compounds were
active against some nematodes and a trematode, but not
against all nematodes. Perhaps this could be due to loss or
change in a target during nematode evolution. Differences in
drug access between species due to difference in the cuticle or
other permeability barriers (i.e., the schistosome’s tegument)
may also play a role.
■ CONCLUSIONS
In this study, we investigated the structure−activity relation-
ship of the DHB compounds, defined essential features for
anthelmintic action, and broadened the active series by the
discovery of dihydrobenzoquinolinone compounds with
activity against T. muris adult motility. We have also
demonstrated that DHB and related compounds have activity
against multiple helminths across different phyla: against the
nematodes B. malayi and H. polygyrus as well as T. muris and
against the trematode S. mansoni. What we have not achieved,
however, is the substantive improvement in potency from the
20−50 μM range that would be desirable to progress this series
with confidence to in vivo testing. Open science, where
information is disclosed more freely than in traditional models,
is proposed to accelerate drug discovery and make it more cost
efficient, especially in the context of neglected diseases.65,66 We
have therefore decided to report our progress at this point. We
note that we do not yet know the target of the DHB/DBQ
compounds in helminths. Identifying this target may facilitate
the boost in activity for which we are striving.
■ METHODS
Ethics Statement. All experimental procedures involving
T. muris were approved by the University of Manchester
Animal Welfare and Ethical Review Board and performed
within the guidelines of the Animals (Scientific Procedures)
Act, 1986.
All experiments involving B. malayi were approved by the
ethical committees of the University of Liverpool and
Liverpool School of Tropical Medicine (LSTM) and
conducted under Home Office Animals (Scientific Procedures)
Act 1986 (UK) requirements and the ARRIVE guidelines.
Figure 6. Measurement of the activity of 30 DHB compounds against S. mansoni schistosomula using the Roboworm platform. (A) Each point is
the measured effect of one compound on the two parameters, motility and phenotype. The phenotype score is calculated by a computational model
that assesses morphological and texture properties of the schistosomula.53 Compounds were screened at 50 μM. Auranofin was the positive control
(screened at 10 μM). Dotted box indicates the threshold for activity in this assay: −0.15 for phenotype and −0.35 for motility; compounds must be
below this threshold for both parameters to be considered a hit.53,55 Compounds were screened in duplicate on two or three separate occasions,
and the data represent the average scores of these experiments. (B) Representative images of schistosomula treated with controls, 22, and 35. (C)
Structure of 35 (OX03828). The structure of 22 (OX03824) is shown in Table 1.
Table 2. EC50 Values for Compounds Active in the S.
mansoni Schistosomula Roboworm Assaya
EC50 in S. mansoni schistosomula Roboworm
assay (μM)
compound phenotype motility
9 OX03144 28.4 28.0
25 OX03146 25.5 25.6
15 OX03596 29.1 26.8
34 OX03599 14.2 18.3
17 OX03601 24.4 20.6
36 OX03698 28.5 26.6
6 OX03707 32.7 29.3
22 OX03824 40.9 36.8
35 OX03828 25.7 20.7
aCompounds were screened at 10, 20, 30, 40, and 50 μM, and EC50
values were calculated for each of the screening parameters,
phenotype, and motility.
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The work on H. polygyrus was approved by the local
veterinary agency based on Swiss cantonal and national
regulations (permission no. 2070).
For experiments involving S. mansoni, all procedures
performed on mice adhered to the United Kingdom Home
Office Animals (Scientific Procedures) Act of 1986 (project
licenses PPL 40/3700 and P3B8C46FD) as well as the
European Union Animals Directive 2010/63/EU and were
approved by Aberystwyth University’s (AU) Animal Welfare
and Ethical Review Body (AWERB).
Chemical Synthesis. Compounds were synthesized from
commercially available starting materials and fully character-
ized by nuclear magnetic resonance spectroscopy and mass
spectrometry. Full experimental details and analytical data are
provided in the Supporting Information.
Isolation of T. muris Adults. Male and female severe
combined immunodeficient (SCID) mice were bred in house
at the University of Manchester and used at age 8−12 weeks.
Mice were maintained at a temperature of 20−22 °C in a 12 h
light, 12h dark lighting schedule in sterile, individually
ventilated cages with food and water ad lib.
The parasite was maintained and the infectivity of the
administered T. muris eggs was assessed as previously
described.67,68 For generation of adult T. muris worms, 150
infective eggs were given per oral gavage in water to each SCID
mouse. Thirty-five days post infection, mice were sacrificed via
schedule one methods. At necropsy, the cecae and colons were
removed, opened longitudinally, and washed with prewarmed
RPMI-1640 media supplemented with penicillin (500 U/mL)
and streptomycin (500 μg/mL). Adult T. muris worms were
gently removed using fine forceps under a dissecting
microscope and maintained at 37 °C in RPMI-1640 media
supplemented with penicillin (500 U/mL) and streptomycin
(500 μg/mL).
T. muris Adult Motility Assay. Single adult worms were
placed in microplate wells containing 100 μL of RPMI-1640
medium, penicillin (500 U/mL), streptomycin (500 μg/mL),
and 1 μL (1% v/v) dimethyl sulfoxide (DMSO) or compound
dissolved in DMSO. Assay plates were incubated at 37 °C with
5% CO2. The INVAPP system was used to quantify worm
motility.39,69 Movies of the whole plate were recorded (20
frames, 100 ms interval) and motility determined by
thresholding the variance of each pixel in the image over
time.70 Compounds were initially tested at 100 μM. Those
showing activity were also tested at lower concentrations,
typically 50 and 75 μM, and EC50 estimates were measured for
compounds of interest using the a log−logistic model and the
R package drc.45
B. malayi Parasite Production. The life cycle of B. malayi
was maintained in Aedes aegypti mosquitoes (Liverpool strain)
and inbred Mongolian gerbils housed at the Biomedical
Services Unit, University of Liverpool under specific pathogen-
free conditions. Microfilariae were harvested from experimen-
tally infected Mongolian gerbils via catheterization under
anesthesia and fed to mosquitoes in human blood at 20 000
mf/ml using artificial membranes heated to 37 °C. Mosquitoes
were reared for 14 days with daily sugar-water feeding to allow
development to larval stage (BmL3). At day 14, BmL3 were
collected from infected mosquitoes by stunning at 4 °C,
crushing and concentrating using a Baermann’s apparatus and
RPMI-1640 media. Male IL-4Rα−/−IL-5−/− BALB/c mice
(gifted by Prof. Achim Hoerauf, University of Bonn, Germany)
aged 6−8 weeks, weighing 18−24 g were infected intra-
peritoneally with 150 BmL3 and left for 12 weeks to develop to
patent adult stage as previously detailed.71
B. malayi Microfilaria Assay. Brugia malayi microfilariae
(mf) were harvested from Mongolian gerbils via intraperitoneal
lavage and purified using PD-10 columns (Amersham). Mf
densities were then adjusted to 8000/well in complete medium
consisting of RPMI-1640 supplemented with 1% penicillin−
streptomycin, 1% amphotericin B, and 10% FBS within 96 well
plates.
Thirty-three test compounds (10 mM stock in 100%
DMSO) were initially tested against mf. Compounds were
diluted to 10 μM in complete medium and added to the plated
mf. Three replicates were used for each compound, and each
plate included ivermectin (50 μM) as a positive control and
DMSO (0.5% v/v) as a negative control. Assay plates were
incubated for 6 days at 37 °C, 5% CO2. Mf were scored daily
for motility as a proxy of nematode health using a 5 point
scoring system (4 = fully motile, 0 = no motility) as described
previously.72 Compounds found to reduce motility were
progressed to a secondary screen, whereby the MTT assay
was employed at day 6 to assess parasite viability quantitatively.
For this, excess media was removed from wells, and mf were
incubated with 0.5 mg/mL MTT (3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (Merck) in PBS at 37 °C
for 90 min. After washing in PBS and centrifugation, mf pellets
were incubated in 100% DMSO for 1 h at 37 °C to solubilize
the blue formazan product. Samples were read at OD 490 nm
on a 96-well plate reader (Varioskan, Bio-Rad). Compounds
exhibiting the greatest activity on parasite viability were
progressed further for drug dose titration assays.
B. malayi Adult Assay. Adult female B. malayi 12−24
weeks of age were isolated from susceptible IL-4Rα−/−IL-5−/−
immunodeficient mice, washed in PBS, and added to lymphatic
endothelial cell cocultures (HMVECdly; LEC; Lonza) at a
density of two parasites per well. Successful test compounds
from the mf assay were diluted to 10 μM and added to the
trans-wells in 6 mL endothelial basal media with supplements
(EGM-2 MV; Lonza). Twelve replicates (n = 6 wells) were set
up per group with flubendazole (10 μM; Sigma) and DMSO
(0.5% v/v) added as controls. Plates were incubated for 14
days at 37 °C, 5% CO2 with daily motility scoring, as above.
Individual parasites were taken for MTT analysis at day 14.
Heligmosomoides polygyrus Assay. H. polygyrus larvae
(L3) were obtained by filtering the feces of infected mice and
cultivating the eggs on an agar plate for 8−10 days in the dark
at 24 °C. Thirty to forty L3 were placed in each well of a 96-
well plate for each compound in the presence of 100 μL RPMI
1640 (Gibco, Waltham MA, United States) culture medium
supplemented with 5% amphotericin B (250 μg/mL, Sigma-
Aldrich, Buchs, Switzerland) and 1% penicillin 10 000 U/mL,
and streptomycin 10 mg/mL solution (Sigma-Aldrich, Buchs,
Switzerland) with the test drugs (100 μM concentration).
Worms were kept at room temperature for 72 h; for evaluation,
50−80 μL of hot water (≈80 °C) was added to each well, and
the larvae that responded to this stimulus (the moving worms)
were counted. The proportion of larval death was determined.
Compounds were tested in duplicate at 100 μM. Control wells
were included in each experiment, which included the highest
amount of solvent (1% DMSO).
S. mansoni Roboworm Assay. Biomphalaria glabrata
(NMRI and the previously described pigmented strains73)
infected previously with S. mansoni (Puerto Rican strain)
miracidia were exposed for 1.5 h under light at 26 °C.
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Cercariae were collected and mechanically transformed into
schistosomula as previously described.74 Mechanically trans-
formed schistosomula were subsequently prepared for high
throughput screening (HTS) on the Roboworm platform
according to Crusco et al.75 All compounds were tested in
duplicate during dose response titrations (50, 40, 30, 20, and
10 μM in 0.625% DMSO). Assay controls included 10 μM (in
0.625% DMSO) auranofin (positive control; Sigma-Aldrich,
UK) and 0.625% DMSO (negative control). Schistosomula
phenotype and motility were quantified after 72 h coculture
with compounds as previously described.53 Compounds
passing both phenotype (−0.15) and motility (−0.35)
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